Markers of Defective Membrane Remodelling in Scott-like Syndromes

Terminated

• Conditions: Familial Bleeding Disorder; Scott Syndrome; Unexplained Isolated Provoked Hemorrhages
• Interventions: Other: Blood withdrawal

• Registration Number: NCT00617721
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Purpose: Identification of the gene(s) involved in plasma membrane remodelling. Identification of the circulating markers affected by the defective membrane remodelling in a collection of families with unexplained provoked hemorrhages and evaluation of their prognosis value in the assessment of the hemostatic cellular response.Hypothesis: Scott syndrome is rare a familial disorder characterized by provoked haemorrages in homozygous-type patients due to isolated membrane remodelling deficiency. Membrane remodelling is necessary for cellular hemostatic responses.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2008-02-05
• Study First Submitted QC: 2008-02-05
• Study First Posted: 2008-02-18
• Study Start: 2008-06
• Status Verified: 2016-06
• Last Update Submitted: 2016-06-16
• Last Update Posted: 2016-06-17

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

• Patients with unexplained provoked hemorrhages (surgery, tooth extraction, birth ...), and associated with reduced prothrombin consomption (residual prothrombine in serum > à 5%).
• Family members of the patients defined above, with or without unexplained hemorrhages (symptomatic or not).
• Patient's approval based on detailed information given by the pratician

Exclusion Criteria

• Patients with primary hemostasis defect or defective blood coagulation factor(s) possibly explaining the bleeding disorder.
• Anémia,
• patients known to be affected by Factor V New York .
• Patients enrolled in a previous clinical study, the exclusion period of which is not yet completed. - Collaboration to the study rejected by the patient
• Patients that are not registered for medical care social insurance.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Blood withdrawal	patients with unexplained bleeding disorder
2	Blood withdrawal	healthy volunteers

Trial Locations

Locations (5)

Hôpital Antoine Béclère, Service d'Hématologie Biologique; 🇫🇷 Clamart, France

Laboratoire d'Hémostase et d'Immunologie, Centre Hospitalier; 🇫🇷 Le Mans, France

Laboratoire d'Hématologie, Hôpital Robert Debré; 🇫🇷 Reims, France

Laboratoire d'Hématologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg; 🇫🇷 Strasbourg, France

Service d'Hématologie Biologique, Hôpital Pierre Zobda Quitman; 🇲🇶 Fort de France, Martinique